This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
by Zacks Equity Research
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
NVSPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
by Zacks Equity Research
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
RARENegative Net Change ALNYPositive Net Change ALDXNegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
by Sundeep Ganoria
MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.
MRNAPositive Net Change MRKPositive Net Change SKYDNegative Net Change
biotechs internet medical multi-sector-conglomerates pharmaceuticals vaccines
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
by Ahan Chakraborty
LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.
LLYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
by Ekta Bagri
Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
BMYPositive Net Change GERNNegative Net Change KROSNegative Net Change
biotechs pharmaceuticals
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
by Zacks Equity Research
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
BBIOPositive Net Change BMRNPositive Net Change ASNDPositive Net Change
biotechs medical
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
by Debanjana Dey
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
ELTPNegative Net Change AYTUNegative Net Change
biotechnology biotechs medical pharmaceuticals
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
by Zacks Equity Research
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
HALOPositive Net Change JNJPositive Net Change ARGXPositive Net Change HOWLNegative Net Change
biotechs
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
by Ahan Chakraborty
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
NVOPositive Net Change LLYPositive Net Change ALTNegative Net Change MDGLPositive Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
by Zacks Equity Research
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
INSMPositive Net Change VKTXNegative Net Change ACIUNo Net Change
biotechs medical